
OXFORD BIODYNAMICS PLC — Investor Relations & Filings
Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Holding(s) in Company | 2026-03-30 | English | |
| Holding(s) in Company | 2026-03-20 | English | |
| OBD to present at PMWC 2026 | 2026-03-03 | English | |
| Change of Nominated Adviser | 2026-02-17 | English | |
| Group of companies' accounts made up to 2025-09-30 | 2026-02-07 | English | |
| Holding(s) in Company | 2026-01-27 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
8 filings
| |||||
| 33090381 | Holding(s) in Company | 2026-03-30 | English | ||
| 32999131 | Holding(s) in Company | 2026-03-20 | English | ||
| 32870571 | OBD to present at PMWC 2026 | 2026-03-03 | English | ||
| 28145821 | Change of Nominated Adviser | 2026-02-17 | English | ||
| 46825992 | Group of companies' accounts made up to 2025-09-30 | 2026-02-07 | English | ||
| 13423399 | Holding(s) in Company | 2026-01-27 | English | ||
| 13336071 | Result of AGM | 2026-01-26 | English | ||
| 13321261 | Board Change | 2026-01-26 | English | ||
|
2025
7 filings
| |||||
| 10596208 | Publication of 2025 Annual Report | 2025-12-22 | English | ||
| 10182820 | Preliminary Results and Notice of AGM | 2025-12-16 | English | ||
| 9703457 | Notice of Results | 2025-12-09 | English | ||
| 9132673 | Statement re share price, update on EpiSwitch PSE | 2025-12-03 | English | ||
| 8620070 | Holding(s) in Company | 2025-11-25 | English | ||
| 8250005 | Holding(s) in Company | 2025-11-12 | English | ||
| 8213853 | Holding(s) in Company | 2025-11-11 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for OXFORD BIODYNAMICS PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Jasper Therapeutics, Inc.
A clinical-stage biotech developing therapies targeting mas…
|
JSPR | US | Professional, scientific and te… |
|
Jeevan Scientific Technology Limited
A CRO providing Phase I-IV trials, BA/BE research, and phar…
|
538837 | IN | Professional, scientific and te… |
|
J. Molner AS
A CDRO developing generic sterile injectable and dermatolog…
|
JML | EE | Professional, scientific and te… |
|
JOINN Laboratories (China) Co., Ltd.
Comprehensive CRO providing end-to-end preclinical drug dis…
|
6127 | HK | Professional, scientific and te… |
|
JOINN LABORATORIES (CHINA) CO., LTD.
A CRO specializing in non-clinical safety assessment and ph…
|
603127 | CN | Professional, scientific and te… |
|
Kadimastem Ltd.
Clinical-stage cell therapy company developing treatments f…
|
KDST | IL | Professional, scientific and te… |
|
KAINOS MEDICINE, INC.
Develops small molecule therapeutics for neurodegenerative,…
|
284620 | KR | Professional, scientific and te… |
|
Kairos Pharma, LTD.
Develops oncology therapies targeting drug resistance and i…
|
KAPA | US | Professional, scientific and te… |
|
Kancera
Pharmaceutical company seeking a reverse takeover to levera…
|
KAN | SE | Professional, scientific and te… |
|
KAZIA THERAPEUTICS LTD
Oncology-focused biotech developing targeted therapies for …
|
KZIA | US | Professional, scientific and te… |
OXFORD BIODYNAMICS PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/7829/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=7829 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=7829 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=7829 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 7829}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for OXFORD BIODYNAMICS PLC (id: 7829)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.